AcelRx Pharmaceuticals Inc (ACRX)

Overview

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company with a sharp focus on developing and commercializing innovative therapies for the treatment of acute pain. Originating as SuRx, Inc., the company underwent a rebranding to AcelRx Pharmaceuticals, Inc. in August 2006. Since its establishment in 2005, AcelRx has been committed to addressing the critical need for effective pain management solutions, with its headquarters situated in Hayward, California. A major driving force behind the company's research and development activities is the quest to provide patients suffering from moderate-to-severe acute pain with safer, more effective treatment options, thereby improving their quality of life.

Products and Services

• DSUVIA and DZUVEO:

A lead product candidate by AcelRx, DSUVIA (in the U.S.) and DZUVEO (outside the U.S.), is a 30 mcg sufentanil sublingual tablet designed for the treatment of moderate-to-severe acute pain. This innovative approach to pain management offers a non-invasive yet potent solution for pain relief.

• ZALVISO:

ZALVISO is a patient-controlled analgesia system that privileges hospital patients suffering from moderate-to-severe acute pain by allowing them to self-dose with sufentanil sublingual tablets. This system empowers patients to manage their pain more effectively and independently.

• ARX-02:

Currently in Phase 2 clinical trials, ARX-02 is being developed for the treatment of cancer breakthrough pain in opioid-tolerant patients. This product candidate aims to provide targeted relief for sudden episodes of intense pain in cancer patients.

• ARX-03:

ARX-03 is under Phase 2 clinical trials for the dual purpose of treating procedural anxiety and acute pain. This investigational therapy seeks to alleviate the distress and discomfort associated with medical procedures.

• Niyad:

Niyad is a regional anticoagulant designed for the extracorporeal circuit. This product candidate represents AcelRx's venture into treatments that support the management of blood clotting during medical procedures and treatments.

• LTX-608:

As an investigational product, LTX-608 is a nafamostat formulation for direct IV infusion being explored for diverse applications, including antiviral treatment of COVID-19, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. This broad-spectrum initiative underscores AcelRx's commitment to addressing emergent global health challenges.

• Fedsyra:

Fedsyra, an ephedrine pre-filled syringe, contains 10 ml of a 3 mg/ml ephedrine hydrochloride solution for injection. This product aims at offering a precise and controlled solution for managing hypotension during surgery.

• Phenylephrine Pre-filled Syringe:

This product contains 10 ml of a 50 mcg/ml phenylephrine solution for injection, designed to manage hypotension. Similar to Fedsyra, it exemplifies AcelRx's dedication to enhancing the safety and efficiency of acute care interventions.